Tuğba Çiçek

Dr. Tuğba Çiçek


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2022 in Sao Paulo Medical Journal
Verified
Journal Article
Open access
MŞMelahat Uzel Şener
Melahat Uzel Şener
TÇTuğba Çiçek
Tuğba Çiçek
AOAyperi Ozturk
Ayperi Ozturk
BACKGROUND: Coronavirus disease 2019 (COVID-19) can cause cytokine release syndrome (CRS), which leads to high mortality rates. Tocilizumab suppresses CRS by blocking the signal transduction of interleukin-6 (IL-6). OBJECTIVE: To evaluate the clinical and laboratory parameters associated with mortality among patients receiving tocilizumab treatment. DESIGN AND SETTING: Retrospective observational study conducted in the chest disease departments of two different training and research hospitals in the center of Ankara, Turkey. METHODS: Patients who were hospitalized and treated with tocilizumab in September 2020 were retrospectively analyzed. Their laboratory parameters and clinical characteristics were obtained from the hospital information system database. Comparative analyses were performed between the patients who died and the ones who survived. RESULTS: A total of 58 patients who received tocilizumab treatment were included in this study, among whom 35 (60.3%) died. There was no difference between the mortality and survival groups in terms of white blood cell (WBC), neutrophil, lymphocyte, ferritin or C-reactive protein (CRP) levels detected on admission. WBC, lymphocyte, neutrophil and CRP levels measured on the third and fifth days after tocilizumab administration were found to be significantly lower in the survival group (P < 0.05). In multiple logistic regression analysis, age and oxygen saturation were determined to be independent risk factors for mortality. CONCLUSION: Persistently high WBC, CRP and neutrophil levels and low lymphocyte levels could be considered to be valuable indicators of mortality among COVID-19 patients treated with tocilizumab. Age and low oxygen saturation are independent risk factors for mortality among patients receiving tocilizumab treatment.

12 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NKNagihan Durmuş Koçak
Nagihan Durmuş Koçak
NTNuri Tutar
Nuri Tutar
GÇGizem Çil
Gizem Çil
EAEmine Afşin
Emine Afşin
AŞAyşegül Şentürk
Ayşegül Şentürk
APAyşe Pala
Ayşe Pala
Background/Objectives: The association between past coronavirus disease-19 (COVID-19) infection and pulmonary thromboembolism (PTE) is a potential research topic. We aimed to research the prevalence of previous COVID-19 infection in patients with PTE and to determine whether there is a difference in embolism severity in these cases. Methods: Study design: Multicenter, observational, cross-sectional. Patients diagnosed with PTE between 11 March 2022 and 11 March 2023 were prospectively included in this study, excluding cases with PTE along with active COVID-19, patients under the age of 18, and pregnant patients. Group 1 consisted of PTE cases with previous COVID-19, and Group 2 consisted of PTE cases without previous COVID-19. Key variables are D-Dimer level, right ventricle/left ventricle (RV/LV) ratio, simplified pulmonary embolism severity score, and treatment type. Results: A total of 1185 patients (Group 1; n = 360, Group 2; n = 825) were included in this study. The proportion of patients with RV/LV ratio > 1 on computed tomography pulmonary angiography (CTPA) was significantly high in Group 2 compared to Group 1 (27.9% vs. 19.7%, p = 0.003). In multivariate logistic regression analysis, the absence of any identifiable risk factor for PTE was found to be a 0.46-fold protective factor in the presence of previous COVID-19 (OR: 0.456 95% CI: 0.274–0.760, Wald = 9.070, df = 1, p = 0.003) and an RV/LV ratio > 1 on CTPA was found to be a 0.60-fold protective factor (OR: 0.603, 95% CI: 0.365–0.998, Wald = 3.874, df = 1, p = 0.049). Conclusions: The prevalence of previous COVID-19 infection in PTE cases was 30.4%, and 26.3% of idiopathic cases had previous COVID-19 infection. Although the parameters related to embolism severity were higher in the non-COVID-19 group, multivariate analyses revealed a 2.2-fold increased risk for idiopathic PTE and a 1.7-fold increased risk for RV/LV ratio > 1 on CTPA in patients without COVID-19 compared to those with prior COVID-19.

Verified
Journal Article
Open access
PDF file
TÇTuğba Çiçek
Tuğba Çiçek
KYKerim Yeşildağ
Kerim Yeşildağ
Background: Intermediate-high-risk acute pulmonary embolism (APE) presents a clinical challenge, as patients are hemodynamically stable at admission yet carry a substantial risk of deterioration requiring rescue thrombolytic therapy. This study evaluated whether admission complete blood count-derived inflammatory indices, particularly the Systemic Inflammation Response Index (SIRI), are associated with subsequent thrombolytic therapy requirement. Methods: In this retrospective cohort study, 134 patients with computed tomography pulmonary angiography–confirmed intermediate-high-risk APE, classified according to 2019 ESC guidelines, were grouped based on the need for rescue thrombolytic therapy (n = 52) versus no thrombolytic therapy (n = 82). Inflammatory indices were calculated from admission blood samples, and multivariable logistic regression and ROC analyses were performed. Results: Patients requiring thrombolysis had significantly higher SIRI, SII, hs-troponin I, and systolic pulmonary artery pressure (SPAP), and lower lymphocyte counts. In multivariable analysis, SIRI (OR = 2.08, 95% CI 1.37–3.13), SPAP (OR = 1.21, 95% CI 1.06–1.37), and troponin (OR = 1.01 per 10 ng/L increment, 95% CI 1.00–1.01) were independently associated with thrombolytic therapy requirement. Conclusions: SIRI, SPAP, and hs-troponin I were independently associated with thrombolytic therapy requirement in intermediate-high-risk APE. These findings are hypothesis-generating and warrant prospective validation before clinical implementation.

15 March 2021 in Balkan Medical Journal
Verified
Journal Article
Open access
ETElif Tanrıverdi
Elif Tanrıverdi
NTNuri Tutar
Nuri Tutar
AŞAyşegül Şentürk
Ayşegül Şentürk
ABAyşe Bahadır
Ayşe Bahadır
NANimet Aksel
Nimet Aksel
BSBilge Salık
Bilge Salık
Background: Direct oral anticoagulants (DOACs) have been used in acute pulmonary thromboembolism as an alternative to warfarin due to drug interactions, narrow therapeutic range, and necessary close International Normalized Ratio (INR) monitoring. Phase 3 study results have reported that these drugs are at least as effective as warfarin and beneficial in terms of bleeding; however, studies that present up-to-date life data are necessary. Aims: To evaluate the frequency of using DOACs, which are prescribed with a limited number of indications in our country, and real-life data results. Study Design: Cross-sectional study Methods: This cross-sectional survey collected the clinical data (history, current treatment, treatment duration, etc.) of patients with pulmonary thromboembolism and who applied to the physician for follow-up between October 15, 2019, and March 15, 2020. The researchers kept the patient records sequentially. Results: Data from 836 patients with acute pulmonary thromboembolism from 25 centers were collected, and DOAC was used in 320 (38.5%) of them. The most preferred DOAC was rivaroxaban (n = 294, 91.9%). DOAC was mostly preferred because it could not provide an effective INR level with warfarin (n=133, 41.6%). Bleeding was observed in 13 (4%) patients. Conclusion: The use of direct oral anticoagulants is becoming almost as widespread as conventional therapy. Real-life data results are important for their contribution to clinical practice.

1 January 2015 in World Allergy Organization Journal
Verified
Journal Article
Open access
PDF file
AÖAysenaz Özcan
Aysenaz Özcan
ADAdile Berna Dursun
Adile Berna Dursun
TÇTuğba Çiçek
Tuğba Çiçek

21 March 2020 in TURKISH JOURNAL of CLINICS and LABORATORY
Verified
Journal Article
Open access
PKPınar Akın Kabalak
Pınar Akın Kabalak
TÇTuğba Çiçek
Tuğba Çiçek
ÖÇÖmer Faruk Çiçek
Ömer Faruk Çiçek
DKDerya Kizilgöz
Derya Kizilgöz
ÜYÜlkü Yilmaz
Ülkü Yilmaz
Aim: The Pulmonary Embolism Rule-out Criteria (PERC) rule is a diagnostic algorithm to exclude pulmonary embolism (PE). Even it is not widely used in routine practice, has better negative predictive value in low-risk populations among existed clinical assessment tests. We aimed to examine availability of PERC rules combined with Wells score in a pulmonary emergency ward.Material and Methods: A retrospective hospitalized database study was conducted with 163 patients. All patients who underwent radiological investigation due to suspicious for PE were included. We calculated prevalence of PE in group of PERC negative and PERC positive. All PERC parameters were evaluated solely for risk of PE.Results: PERC positivity was 82.4% in patients diagnosed with PE. There were no significant differences in terms of PERC positivity between PE+ and PE- groups (p=0.336). False positivity rate for moderate to high Wells score was 36.1%. Frequency of PERC negativity among PE negative patients was only %36.1 and %17.6 in PE positive group (p=0.75 and r=-0.025). The sensitivity of the PERC test was 82.3%, specificity 19.6%, PPV 63.1%, NPV 40%, false positivity rate 36.8% and false negativity rate 60%. Among patients with moderate to high wells, 61 patients were diagnosed PE and 14 of them were PERC negative.Conclusion: Our study suggests that PERC scoring system even combined with Wells score does not sufficient enough to prevent unnecessary irradiative imaging studies in a pulmonary emergency ward.